Caplin Point Gets USFDA Nod

  Published 1 year ago

Caplin Point received USFDA approval for generic Milrinone injection, targeting acute decompensated heart failure treatment.

  • Approval covers two Milrinone infusion dosage forms, ensuring availability in safe, effective single-dose infusion bag packaging.
  • Milrinone Lactate Injection recorded $11 million in US sales for the 12 months ending July 2025.
  • Caplin Point expands presence in regulated US markets via subsidiaries Caplin Steriles and Caplin Steriles USA Inc.

You might like these

Cigarette Stocks Fall Amid GST Overhaul

India to Manufacture SURYA Launcher

Silver Shines as India’s New Bet

Ircon International Q4 & FY25 Performance

INA Group Hits 4 GW PV Capacity

BofA: India Equities, Cautious Now, Bullish Long-Term

Surya Roshni Secures 3LPE Pipe Order, Expands Production

News that matters the most ⚡